PROJECT SOLUTIONS
MF BIOTECH believes in rigorous development strategies and efficient execution. We help innovative biotech and pharma projects with customized and targeted support to meet their goals.
BIOPHARMACEUTICALS & PRODUCT TYPES
Protein drugs, monoclonal antibodies, fusion proteins
mRNA-based drugs and vaccines
Gene therapies, genetically modified organisms (GMOs), genome editing
Cellular immunotherapies
Regenerative therapies
Oncolytic viruses
Bacteriophages
Small molecules
First-in-class therapies
Orphan drugs
Biosimilars
Combination products
We provide our services throughout all development phases, from the idea to product approval and beyond.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Early Stage
CMC
Nonclinical
Clinical
MAA/ BLA
Post-Approval
Global Development Strategy
We build and execute your product-specific global development strategy from early stage development to product launch. We provide guidance on your functional development plans including all regulatory, CMC, clinical and non-clinical aspects.
-
Preparation of integrated development strategy and definition of key development milestones for CMC, non-clinical, clinical, regulatory
Preparation of global regulatory strategy till approval including strategic considerations and requirements for EU and US
Assessment of options and scenarios to accelerate product development
Target product profile (TPP) definition
Competitive landscape analysis and regulatory intelligence
-
Preparation of functional project plans for CMC, clinical and nonclinical develop ready for execution
Technical gap analyses incl. proposals for remediation
Comprehensive time and budget planning for complete development program
Planning of development project scenarios for decision-making
Writing of Biosimilarity assessment report
-
Management of development programs, complex projects, and multi-project portfolios including project planning and tracking of timelines, quality, costs
Operational support for clinical trials via CTIS
Planning and execution of tech transfer projects
Implementation of project management processes and tools
CMO and vendor management
Project reporting and performance measurement
Crisis and change management
Management of grants and public funding
Regulatory Affairs
We support you with regulatory and medical writing of your submissions to authorities. We provide flexible and fast hands-on support for your day-to-day operations to get things done on time and where you need it.
-
Preparation and management of scientific advice meetings and regulatory interactions including meeting request and briefing documentation, organization and management of procedure (EMA, FDA, national competent authorities, Health Canada)
Writing and preparation of applications for grants and public funding
EU representative and primary contact in all dealings with EMA
-
Preparation of requests for regulatory expedited programs such as PRIME, breakthrough, RMAT designation
Preparation of applications for orphan drug designation (ODD) and humanitarian use device (HUD) designation
Preparation and management of SME applications to EMA
Acting as Interim Regulatory Affairs Professional in your team
-
Writing of investigational medicinal product dossier (IMPD), investigational new drug (IND) applications
Writing of Investigator's Brochure
GMO documentation for clinical trial applications in the EU, environmental risk assessment (ERA)
-
Writing of marketing authorization application (MAA), biologics license application (BLA)
Let’s work together.
PROJECTS
A selection of our projects, which we are proud of.
- Active pharmaceutical ingredients
-
Bacteriophage
- Jul 24, 2024 EU development strategy
-
Cell & gene therapy
- Jul 24, 2024 Orphan drug designation
- Jul 24, 2024 National scientific advices in EU and Canada, IMPD
- Combination product
-
Fusion protein
- Jul 24, 2024 EMA scientific advice
- Genetically modified organism
- Medical device
-
Monoclonal antibody
- Jul 24, 2024 Program management of biosimilar development program
- Jul 24, 2024 MAA and Day 120 responses, immunogenicity assessment report
- Jul 24, 2024 IMPD
- Jul 24, 2024 EMA scientific advices and development support for biosimilar development program, biosimilarity assessment report
- Jul 24, 2024 Program lead for biosimilar development program
-
Oromucosal immunotherapy
- Jul 24, 2024 IMPD
-
Recombinant protein
- Jul 24, 2024 MAA and QOS/Module 3
- Jul 24, 2024 EMA scientific advice
- Jul 24, 2024 US and EU biosimilar development strategy
- Jul 24, 2024 Project management of inhaled protein drug
-
Small molecule
- Jul 24, 2024 EU and US development strategy, IND, orphan drug designation strategy
- Jul 24, 2024 EU national scientific advices, IMPD
- Jul 24, 2024 Regulatory support for MAA/ BLA procedures
-
Synthetic peptide
- Jul 24, 2024 CMC gap analysis
- Various small molecules
- mRNA
EXPANDED CAPABILITIES
Coaching & Workshops
We recognize the complexity of biopharmaceutical development and thus the value of specialized training for professionals. We teach startups, developers, and entrepreneurs how to bring your product development strategy to the next level.
Tailor-made coaching and training workshops for biopharmaceutical start-ups, development teams and academia
Enable teams with hands-on knowledge and best-in-class tools to establish product-specific development strategy and to execute development plans effectively
Address key development issues in areas for CMC, nonclinical, and clinical development
Strategy & Operations Solutions
Our journey together doesn’t have to end once regulatory approval has been attained. We also help pharmaceutical companies navigate the complexities of bringing their products to market and maximizing their commercial success post-approval.
Comprehensive market analysis, competitive landscape evaluation, and go-to-market planning
Strategic pricing, sales, and distribution planning to optimize market penetration
Ongoing pharmacovigilance and safety monitoring to maintain product integrity
Supply chain risk management, manufacturing optimization, and quality control enhancements
Scientific Due Diligence
Looking to invest in biopharmaceuticals? Our thorough assessments can help give you confidence in your investment’s scientific and regulatory integrity and deliver the insights and assurance you need to make informed, strategic investment decisions.
In-depth evaluation of scientific data, preclinical, and clinical trial findings
Identification of scientific, technical, and regulatory risks and development of appropriate risk mitigation strategies
Intellectual property review, including patent landscape analysis and freedom-to-operate assessments
Strategic comparison with industry standards and competitor offerings
Your partner for all things biotech.
CONTACT US